医学
化疗
癌症
内科学
回顾性队列研究
缓和医疗
重症监护医学
白蛋白
血清白蛋白
临床终点
肿瘤科
外科
化疗方案
急诊科
胃肠道癌
临床意义
死因
胃肠病学
作者
TAKESHI MATSUBARA,Koki Kawakami,KANA FUJIWARA,KENTO NAKAJIMA,Yuto Yasuda,HIROKI OKAMURA,YURIKO YAMADA,Shunsuke Kaji,Kazunari Ishitobi,Takahito Taniura,Takayuki Tanaka,Tetsu Yamamoto,Masaaki Hidaka
出处
期刊:Anticancer Research
[International Institute of Anticancer Research (IIAR) Conferences 1997. Athens, Greece. Abstracts]
日期:2026-08-31
卷期号:46 (9): 5271-5280
标识
DOI:10.21873/anticanres.18371
摘要
BACKGROUND/AIM: Chemotherapy administered near death is a recognized quality indicator of end-of-life cancer care intensity. However, simple clinical signals to prompt treatment reassessment and coordinate planned end-of-life care remain unclear in advanced gastric cancer. This study evaluated the interval from last chemotherapy to death and explored factors associated with near-end-of-life chemotherapy and failure to transition to a planned end-of-life care setting. PATIENTS AND METHODS: This single-center retrospective study included 53 patients with advanced or recurrent gastric cancer who had complete data regarding final chemotherapy, mortality, and concurrent laboratory findings. The primary endpoint was chemotherapy administration within 30 days of death. A planned end-of-life care setting was defined as a scheduled transition to a palliative care unit, institutional care, or home-based care with visiting nursing support. RESULTS: =0.010). Furthermore, albumin ≤2.9 g/dl and C-reactive protein (CRP) >1.0 mg/dl were associated with failure to transition to a planned care setting. CONCLUSION: Low serum albumin at final chemotherapy may serve as a practical clinical trigger for reassessing treatment continuation and facilitating timely end-of-life care planning in advanced or recurrent gastric cancer.
科研通智能强力驱动
Strongly Powered by AbleSci AI